Maxim analyst Anthony Vendetti lowered the firm’s price target on Hain Celestial to $25 from $30 but keeps a Buy rating on the shares. The analyst cites the company’s Q1 results, with in-line revenue reflecting industry-wide headwinds impacting the supply of baby formula. The firm adds however that while thes supply constraints will persist into Q2, the company has taken sufficient steps to secure access to additional supply and manufacturing capacity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on HAIN:
- Hain Celestial sees FY24 organic net sales up 2%-4% vs prior year
- Hain Celestial reports Q1 adjusted EPS (4c), consensus (6c)
- Hain Celestial Reports Fiscal First Quarter 2024 Financial Results
- HAIN Earnings this Week: How Will it Perform?
- Hain Celestial Announces Fiscal First Quarter 2024 Results Conference Call and Webcast